C-Diff 1st Diagnosis or 1st Recurrence Treatment Study

Have you been diagnosed with C. difficile diarrhea? If so, we want to make you aware of research on a novel treatment for this infection. Please see the opportunity below and call us if you are interested.

We are conducting research on a new agent for the treatment of C. difficile infection in conjunction with Boulder, CO-based Crestone, Inc. The study is "A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared with Oral Vancomycin in Adults with Clostridioides difficile Infection." The study is supported by the National Institute of Allergy and Infectious Diseases (NIAID).

CRS3123 stops C. difficile toxin production which is a main driver of symptoms of C. difficile infection and spares many of the beneficial gut microbes while inhibiting growth of the C. difficile bacteria.

If you are 18 years or older and have a first or second episode of C diff diarrhea, call or email us today to see if you qualify for this study. Study participants will be provided study medications, laboratory analyses, and follow up visits with our providers at no cost. A small stipend and help with transportation to and from the clinical research site may also be available.

In order to qualify for the study, your answers to the following must be YES:

  • Be 18 years of age or older
  • First or second episode of C diff diarrhea

If you are interested in learning more about this study, please fill out the the following.

Consent(Required)
This field is for validation purposes and should be left unchanged.